GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Intangible Assets

Cyprotex (LSE:CRX) Intangible Assets : £0.54 Mil (As of Jun. 2016)


View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Cyprotex's intangible assets for the quarter that ended in Jun. 2016 was £0.54 Mil.


Cyprotex Intangible Assets Historical Data

The historical data trend for Cyprotex's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Intangible Assets Chart

Cyprotex Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.61 3.40 3.10 0.67 0.56

Cyprotex Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 0.67 0.60 0.56 0.54

Cyprotex Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Cyprotex  (LSE:CRX) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Cyprotex Intangible Assets Related Terms

Thank you for viewing the detailed overview of Cyprotex's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyprotex (LSE:CRX) Business Description

Traded in Other Exchanges
N/A
Address
Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines